An observational study in NAFLD and NASH - Nonalcoholic Steatohepatitis, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-09-24.
Sponsored by Cairo University · Observational
Due to the limited data concerning Egyptian population. authors aimed to investigate the differentadipokine gene polymorphism related to non alcoholic fatty liver disease incidence, prognosis and progression to steotosis and also to find different related factors including obesitu, diabetes and liver enzymes level
1,451 studies on the registry are indexed under Fatty Liver; 292 are open to participants now.
This study's enrollment of 224 is above the median of 140 across 397 observational studies indexed under Fatty Liver.
Browse Fatty Liver studies →Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Egyptian diabetic patients diagnosed with NAFLD
Egyptian patients confirmed NAFLD diagnosis diabetic
-
Exclusion Criteria:
healthy volunteers with absence of NAFLD
Genetic: DNA extraction
patients with confirmed NAFLD diagnosis
Genetic: DNA extraction
investigation of DNA polymorphism in patients suffering from NAFLD
investigate adipokine dna polymorphism
to investigate adipokine gene polymorphism associated with prognosis of NAFLD patients
Time frame: 1 months
correlations
to correlate between gene polymorphism and glycated hemoglobin, liver enzyme and obesity
Time frame: 1 month
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cairo University